Clinical Trials Browser

Terminated × atezolizumab × Dermatologic × Clear all

Carcinoma, Merkel Cell

NCT03901573 2025-10-22

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Phase 1/2 Terminated

31 enrolled 12 charts

Dermatologic

Melanoma, Carcinoma, Merkel Cell

NCT03829501 2025-04-02

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Phase 1/2 Terminated

222 enrolled 49 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT03357224 2024-02-22

PARCT

Phase 2 Terminated

26 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT05060003 2024-02-20

Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Phase 2 Terminated

7 enrolled 4 charts

Dermatologic

Melanoma

NCT05110781 2023-09-05

Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site

Phase 2 Terminated

1 enrolled 9 charts

DermatologicHead & Neck

Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

NCT03050060 2022-06-22

Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer

Phase 2 Terminated

21 enrolled 12 charts

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT02303951 2021-02-03

NEO-VC

Phase 2 Terminated

47 enrolled

Dermatologic

Melanoma

NCT02543645 2018-04-30

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Phase 1 Terminated

18 enrolled

BreastDermatologicGenitourinaryHead & NeckThoracic

Clear-cell metastatic renal cell carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Kidney Diseases, Kidney Neoplasms, Melanoma, Neoplasms, Neoplasms by Histologic Type, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

SANTANA-225

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

PARCT

Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site

Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer

NEO-VC

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer